NCT05990660

Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery

Bypass Surgery Incorporating a Negative Pressure Renal Assist Device to Resolve AKI

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: 3ive Labs · Industry
• Sex: All
• Age: 22 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The study is a prospective, non-randomized early feasibility study intended to evaluate the safety and performance of the JuxtaFlow System (also known as the JuxtaFlow Renal Assist Device (RAD)) in participants with pre-existing renal insufficiency who are undergoing cardiac surgery.

Detailed description

The BIPASS-AKI study is intended to evaluate participants who are at an increased risk of developing cardiac surgery-associated acute kidney injury (CSA-AKI), and, subsequently, overall poor outcomes. Patients to be considered for participation include those undergoing elective or urgent in-house on-pump cardiac surgery (to include coronary artery bypass graft, valvular surgery, or combination) and have pre-existing renal insufficiency as defined by a pre-operative eGFR between 15-60 mL/min. Participants meeting inclusion and exclusion criteria will be enrolled into a treatment arm (single-arm study) following the completion of informed consent. Participants will receive implantation of the JuxtaFlow Catheters following completion of the their cardiac surgery while remaining under anesthesia. Treatment with the JuxtaFlow System will be initiated upon the participant's arrival into the intensive care unit and continue for up to 24 hours post-operatively. Preoperative, intra-operative, and post-operative data will be collected on participants to include 15- and 30-day follow-up periods.

Conditions

• Renal Insufficiency
• Acute Kidney Injury

Interventions

Type	Name	Description
DEVICE	JuxtaFlow System	Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters

Timeline

• Start date: 2023-09-28
• Primary completion: 2023-12-28
• Completion: 2024-01-18
• First posted: 2023-08-14
• Last updated: 2024-01-23

Locations

3 sites across 2 countries: Poland, Serbia

Regulatory

• FDA-regulated device study